Comparison diagnostic performance of 18F-Flurodeoxyglucose and 18F-Floroestradiol Positron Emission Tomography/Computed Tomography for Initial Staging in Estrogen Receptor Positive Breast Cancer Patients.
Completed
- Conditions
- Initial staging in ER-positive breast cancer18F-FDG, 18F-FES, 18F-Fluorodeoxyglucose, 18F-Fluroestradiol, ER-positive breast cancer
- Registration Number
- TCTR20230603002
- Lead Sponsor
- ational Cyclotron and PET Centre, Chulabhorn Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 206
Inclusion Criteria
(i) patients with pathologically confirmed breast cancer with estrogen receptor (ER) positive and (ii) patients who were > 18 years old
Exclusion Criteria
(i) patients with fasting blood sugar more than 200 mg/dL; (ii) patients who has history of other cancer; (iii) patients with known ER negative, (iv) patients with unknown ER status; and (iii) patients who were pregnant or during breast feed.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Diagnostic performance of FDG and FES PET/CT at the time of intervention (PET/CT interpretation) sensitivity, specificity, PPV, NPV, and accuracy
- Secondary Outcome Measures
Name Time Method Concordant rate of FDG and FES PET-CT at the time of intervention (PET/CT interpretation) concordant rate,Factor affect degree of FDG and FES uptake at the time of intervention (PET/CT interpretation) Multi-linear regression analysis